Novartis Patent-Cliff Exposure & CMS Drug Spending Portfolio

Novartis (East Hanover, NJ): 123 reconciled FDA prescription therapies (40.9% 2025 to 2030 cliff risk), $14.00B 2024 CMS Part D & Medicaid spend, and 292 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterEast Hanover, NJ
Reconciled FDA Portfolio Therapies123
2025 to 2030 Patent-Cliff Revenue Exposure40.9%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$14.00B
2024 Medicare Part D Spend$10.20B
2024 Medicaid Spend$3.79B
California HCAI SB 17 Filings292 WAC filings (max 28.5% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.